One hundred years after the first description of Alzheimer's disease (AD), the majority of potential AD therapeutic interventions explored in biopharmaceutical and biotechnology companies as well as academic labs are linked directly or indirectly to the pathogenesis of A?. In parallel, major advances in the role of biochemical and neuroimaging biomarkers are expected to improve the patient's diagnosis at an earlier stage, yield surrogate markers to establish efficacy of administered drugs in real time, and directly contribute to the development of a new generation of therapeutic agents.



Objectives:

Discuss AD pathogenesis theories.

Examine the current knowledge of biomarkers, genetic predisposition and imaging in AD.

Review the key components of the development programs in place, as major players targeting disease modification.